Prevalence, chronicity, burden and borders of bipolar disorder

Fagiolini, Andrea; Forgione, Rocco Nicola; Maccari, Mauro; Cuomo, Alessandro; Morana, Benedetto; Dell’Osso, Mario Catena; Pellegrini, Francesca; Rossi, Alessandro

doi:10.1016/j.jad.2013.02.001

Cited by 163 publications

(114 citation statements)

References 89 publications

Supporting

Mentioning

105

Contrasting

Unclassified

Order By: Relevance

“…IPOLAR Disorder (BD) is a lifelong and complex psychiatric syndrome characterized by alternating episodes of mania and depression that can vary in duration and time of occurrence [1], [2]. People with BD experience recurrent and severe swings between elevated mood and depression.…”

Section: Introductionmentioning

confidence: 99%

A Method for Rapid, Reliable, and Low-Volume Measurement of Lithium in Blood for Use in Bipolar Disorder Treatment Management

Qassem

Constantinou

Triantis

et al. 2019

IEEE Trans. Biomed. Eng.

View full text Add to dashboard Cite

Abstract-Goal: Lithium preparations are considered the most reliable mood stabilizers for patients with Bipolar Disorder (BD), and are the most effective at reducing the risk of suicide. However, maintaining blood lithium concentration within the narrow therapeutic range of 0.4-1.2 mEq is crucial but extremely difficult. The aim of this work is to develop a personal lithium blood level analyzer using a novel method of combined optical and electrical impedance spectroscopy to test micro volumes of spiked samples of human blood. Results: Impedance measurements alone showed a limit of detection of less than 0.1 mEq within the therapeutic range, whereas optical measurements could verify the presence of lithium and provide a degree of lithium content. Optical specificity to lithium was further verified in qualitative assessment of lithium spiked blood samples with varying concentrations of sodium. Moreover, analysis of multiple linear regression yielded a prediction model of R2 = 0.322716 and RMSEP =0.223602 for optical measurements only using feature wavelengths, which were found to appear at minima 560 and 605 nm. Combined with impedance measurements, prediction of lithium concentration in samples with unknown lithium content was significantly increased to R2 = 0.876438, and RMSEP = 0.513554. Conclusion:The combination of optical and impedance modalities for determinations of blood lithium resulted in significant improvement to the sensitivity and accuracy of measurement. Significance: Results are complementary of the proposed optoimpedance method, and future work will now focus on the technical development of an integrated and miniaturized system for measurement of lithium levels in blood with a high level of accuracy and sensitivity.

show abstract

Section: Introductionmentioning

confidence: 99%

A Method for Rapid, Reliable, and Low-Volume Measurement of Lithium in Blood for Use in Bipolar Disorder Treatment Management

Qassem

Constantinou

Triantis

et al. 2019

IEEE Trans. Biomed. Eng.

View full text Add to dashboard Cite

show abstract

“…10,33 Lifestyle factors, obesity and psychotropic medicines -in particular second-generation antipsychotics -are likely to play a role. 12,34 Furthermore, blood pressure control may be adversely affected by the presence and severity of affective disorders, including bipolar affective disorder -particularly in its acute phase. Interactions between psychotropic medicines, including antipsychotics and lithium, and antihypertensive medication may also complicate the treatment of both conditions.…”

Section: Local Northamptonshire Minimum Standards Formentioning

confidence: 99%

“…8 Bipolar affective disorder is an episodic illness characterised by periods of depressed and elevated or irritable mood, interspersed with periods of recovery, and affects about 1-2% of people. [8][9][10][11][12] It is increasingly recognised that a significant proportion of people continue to experience residual depressive symptoms in the medium to long term. 11 For the majority, the illness begins in early adulthood (median age of onset 24 years and 27 years respectively for men and women), with the first episode often depressive in nature.…”

mentioning

confidence: 99%

Blood pressure monitoring in psychiatric inpatients with bipolar affective disorder

Kelbrick¹,

Abdaldayim²

2014

Prog Neurol Psychiatry

View full text Add to dashboard Cite

People with bipolar affective disorder are at increased risk of hypertension, but cardiovascular health screening practices in mental health services are inconsistent and often sub‐optimal. Here, the authors describe their audit to identify adults with bipolar affective disorder and comorbid hypertension in an acute psychiatric inpatient unit, and to establish the unit's level of compliance with local and national guidelines with regard to blood pressure monitoring.

show abstract

“…The prevalence in older adults is estimated to range from 0.5%-1%, 1,2 with approximately 10% having a late-onset variant of the illness that includes a first episode of mania occurring after the age of 50. 1 As the course of illness progresses, episodes of depression increasingly predominate over episodes of mania 3,4 and are associated with functional impairment [5][6][7][8] and increased direct and indirect health care costs. 4,8,9 Despite relatively low prevalence among older adults in the community, bipolar disorder is overrepresented as a proportion of geriatric outpatient medical visits, geriatric inpatient admissions (8%-10%), and geriatric emergency department presentations with psychiatric emergencies (17%).…”

mentioning

confidence: 99%

“…1 As the course of illness progresses, episodes of depression increasingly predominate over episodes of mania 3,4 and are associated with functional impairment [5][6][7][8] and increased direct and indirect health care costs. 4,8,9 Despite relatively low prevalence among older adults in the community, bipolar disorder is overrepresented as a proportion of geriatric outpatient medical visits, geriatric inpatient admissions (8%-10%), and geriatric emergency department presentations with psychiatric emergencies (17%). 2,10 Currently, 3 medications are approved by the US Food and Drug Administration (FDA) for the treatment of bipolar depression: the combination of fluoxetine/olanzapine, [11][12][13] quetiapine, 14 and lurasidone.…”

mentioning

confidence: 99%

Efficacy of Lurasidone in Adults Aged 55 Years and Older With Bipolar Depression

Sajatovic

Forester

Tsai

et al. 2016

J. Clin. Psychiatry

View full text Add to dashboard Cite

Objective: The aim of this post hoc analysis was to evaluate the efficacy of lurasidone in patients aged 55 years and older with bipolar depression. Methods: A post hoc analysis was performed on the older adult subgroup (n = 142) of outpatients meeting DSM-IV-TR criteria for bipolar I depression in 2 placebo-controlled, 6-week, randomized, double-blind studies conducted from 2009-2012: a monotherapy study comparing fixed flexibledose ranges of lurasidone 20-60 mg/d or 80-120 mg/d with placebo and an adjunctive therapy study comparing flexible doses of lurasidone 20-120 mg/d with placebo adjunctive to either lithium or valproate. The primary endpoint was mean change at week 6 in the Montgomery-Åsberg Depression Rating Scale (MADRS) total score. Results: In the randomized sample, the proportion of older adults was 88/505 (17.4%) in the monotherapy study and 54/348 (15.5%) in the adjunctive therapy study. In the older adult subgroup in the monotherapy study, mean change at week 6 in the MADRS was significantly greater for lurasidone versus placebo (−14.8 vs −7.1; P = .003; effect size, 0.83; pooled doses), and in the adjunctive therapy study, mean change for lurasidone was not significantly different from placebo (−13.9 vs −11.1; P = .398; effect size, 0.26). Discontinuation rates due to adverse events for lurasidone versus placebo were similar for the monotherapy (6.8% vs 6.9%) and adjunctive therapy (3.8% vs 7.1%) studies. Lurasidone had minimal effects on metabolic laboratory values. Conclusions:The results of these post hoc analyses, which assessed the efficacy of lurasidone in older adults with bipolar disorder, found that monotherapy was significantly effective while adjunctive therapy was not associated with significant improvement. Both monotherapy and adjunctive therapy with lurasidone were safe and well-tolerated in this older adult population. Trial Registration: ClinicalTrials.gov identifiers: NCT00868699, NCT00868452.

show abstract

Prevalence, chronicity, burden and borders of bipolar disorder

Cited by 163 publications

References 89 publications

A Method for Rapid, Reliable, and Low-Volume Measurement of Lithium in Blood for Use in Bipolar Disorder Treatment Management

A Method for Rapid, Reliable, and Low-Volume Measurement of Lithium in Blood for Use in Bipolar Disorder Treatment Management

Blood pressure monitoring in psychiatric inpatients with bipolar affective disorder

Efficacy of Lurasidone in Adults Aged 55 Years and Older With Bipolar Depression

Contact Info

Product

Resources

About